Oncocyte gets Nasdaq notice of prior noncompliance and regained compliance after director death

Insight Molecular Diagnostics Inc.

Director Alfred D. Kingsley died April 25, 2024, causing noncompliance with Nasdaq independent board and audit committee rules.
Effective July 1, 2024, director Andrew Arno was deemed independent and appointed to the audit committee, restoring compliance.
Nasdaq Staff confirmed compliance on July 8, 2024; no further action required.
The company had previously disclosed the independence determination in a Form 8-K filed July 5, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.